337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss
The Readout Loud
00:00
Navigating GLP-1 Challenges in Pharma
This chapter explores the complexities surrounding the pricing, accessibility, and market dynamics of GLP-1 medications. The discussion highlights Eli Lilly's sales shortfall for their weight loss drugs despite high demand, addressing inventory management issues and shifting consumer behaviors. Additionally, it emphasizes the need for improved insurance coverage for obesity treatment as a chronic disease and the systemic changes necessary for better access and affordability.
Transcript
Play full episode
